MedTrace Logo

A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..

NCT04469673 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2020-07-14

No results posted yet for this study

Summary

JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody.

Conditions

  • Hyperlipemia

Interventions

BIOLOGICAL

Biological：JS002

Administered by subcutaneous injection

BIOLOGICAL

Placebo

Administered by subcutaneous injection

Sponsors & Collaborators

  • Shanghai Junshi Bioscience Co., Ltd.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-23
Primary Completion
2020-05-03
Completion
2020-06-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04469673 on ClinicalTrials.gov